HONG KONG — A neurotrophic brain protein has been shown to play an important role in how well cancer patients respond to chemotherapy, according to the findings of a new Chinese study reported Dec. 17, 2016, during the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore.
HONG KONG – A neurotrophic brain protein has been shown to play an important role in how well cancer patients respond to chemotherapy, according to the findings of a new Chinese study reported Dec. 17, 2016, during the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore.
HONG KONG — The cyclin-dependent kinase (CDK) 4/6 pathway inhibitor, ribociclib (LEE011, Novartis AG), in combination with Femara (letrozole, Novartis AG), significantly improved progression-free survival (PFS) in postmenopausal Asian women with advanced breast cancer, in a subanalysis of the MONALEESA-2 trial.
HONG KONG – The cyclin-dependent kinase (CDK) 4/6 pathway inhibitor, ribociclib (LEE011, Novartis AG), in combination with Femara (letrozole, Novartis AG), significantly improved progression-free survival (PFS) in postmenopausal Asian women with advanced breast cancer, in a subanalysis of the MONALEESA-2 trial.
HONG KONG – A new study at Duke-National University of Singapore Medical School (Duke-NUS) has identified a novel network of genes in the brain that, when disrupted, causes epilepsy, offering a new target for developing new antiepileptic drugs.
HONG KONG — A world-first periodontitis vaccine that has been developed by Australian scientists, which could reduce or possibly even eliminate the need for surgery and antibiotics for the management of severe gum disease, has been validated by research published online Dec. 1, 2016, in npj Vaccines.
HONG KONG – A world-first periodontitis vaccine that has been developed by Australian scientists, which could reduce or possibly even eliminate the need for surgery and antibiotics for the management of severe gum disease, has been validated by research published online Dec. 1, 2016, in npj Vaccines.
HONG KONG – The process whereby an extremely potent new antibody can neutralize infection by the Zika virus has been discovered by researchers at Duke-National University of Singapore Medical School (Duke-NUS), a key finding that may lead to development of the first effective Zika virus therapies.
HONG KONG – The process whereby an extremely potent new antibody can neutralize infection by the Zika virus has been discovered by researchers at Duke-National University of Singapore Medical School (Duke-NUS), a key finding that may lead to development of the first effective Zika virus therapies.
